全文获取类型
收费全文 | 153篇 |
免费 | 7篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 21篇 |
妇产科学 | 5篇 |
基础医学 | 18篇 |
口腔科学 | 6篇 |
临床医学 | 4篇 |
内科学 | 34篇 |
皮肤病学 | 2篇 |
神经病学 | 13篇 |
特种医学 | 7篇 |
外科学 | 20篇 |
预防医学 | 13篇 |
药学 | 15篇 |
肿瘤学 | 3篇 |
出版年
2022年 | 4篇 |
2021年 | 6篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 7篇 |
2015年 | 6篇 |
2014年 | 8篇 |
2013年 | 9篇 |
2012年 | 15篇 |
2011年 | 15篇 |
2010年 | 6篇 |
2009年 | 3篇 |
2008年 | 7篇 |
2007年 | 12篇 |
2006年 | 5篇 |
2005年 | 5篇 |
2004年 | 5篇 |
2003年 | 7篇 |
2002年 | 7篇 |
2001年 | 4篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1988年 | 1篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1974年 | 1篇 |
1972年 | 1篇 |
排序方式: 共有161条查询结果,搜索用时 15 毫秒
101.
Pollio G Hoozemans JJ Andersen CA Roncarati R Rosi MC van Haastert ES Seredenina T Diamanti D Gotta S Fiorentini A Magnoni L Raggiaschi R Rozemuller AJ Casamenti F Caricasole A Terstappen GC 《Neurobiology of disease》2008,31(1):145-158
In a comprehensive proteomics study aiming at the identification of proteins associated with amyloid-beta (Abeta)-mediated toxicity in cultured cortical neurons, we have identified Thimet oligopeptidase (THOP1). Functional modulation of THOP1 levels in primary cortical neurons demonstrated that its overexpression was neuroprotective against Abeta toxicity, while RNAi knockdown made neurons more vulnerable to amyloid peptide. In the TgCRND8 transgenic mouse model of amyloid plaque deposition, an age-dependent increase of THOP1 expression was found in brain tissue, where it co-localized with Abeta plaques. In accordance with these findings, THOP1 expression was significantly increased in human AD brain tissue as compared to non-demented controls. These results provide compelling evidence for a neuroprotective role of THOP1 against toxic effects of Abeta in the early stages of AD pathology, and suggest that the observed increase in THOP1 expression might be part of a compensatory defense mechanism of the brain against an increased Abeta load. 相似文献
102.
103.
104.
Sigurd D Süssmuth Salman Haider G Bernhard Landwehrmeyer Ruth Farmer Chris Frost Giovanna Tripepi Claus A Andersen Marco Di Bacco Claudia Lamanna Enrica Diodato Luisa Massai Daniela Diamanti Elisa Mori Letizia Magnoni Jens Dreyhaupt Karin Schiefele David Craufurd Carsten Saft Monika Rudzinska Danuta Ryglewicz Michael Orth Sebastian Brzozy Anna Baran Giuseppe Pollio Ralph Andre Sarah J Tabrizi Borje Darpo Goran Westerberg Paddington Consortium 《British journal of clinical pharmacology》2015,79(3):465-476
AimsSelisistat, a selective SirT1 inhibitor is being developed as a potentially disease-modifying therapeutic for Huntington''s disease (HD). This was the first study of selisistat in HD patients and was primarily aimed at development of pharmacodynamic biomarkers.MethodsThis was a randomized, double-blind, placebo-controlled, multicentre exploratory study. Fifty-five male and female patients in early stage HD were randomized to receive 10 mg or 100 mg of selisistat or placebo once daily for 14 days. Blood sampling, clinical and safety assessments were conducted throughout the study. Candidate pharmacodynamic markers included circulating soluble huntingtin and innate immune markers.ResultsSelisistat was found to be safe and well tolerated, and systemic exposure parameters showed that the average steady-state plasma concentration achieved at the 10 mg dose level (125 nm) was comparable with the IC50 for SirT1 inhibition. No adverse effects on motor, cognitive or functional readouts were recorded. While circulating levels of soluble huntingtin were not affected by selisistat in this study, the biological samples collected have allowed development of assay technology for use in future studies. No effects on innate immune markers were seen.ConclusionsSelisistat was found to be safe and well tolerated in early stage HD patients at plasma concentrations within the anticipated therapeutic concentration range. 相似文献
105.
Sebastian Drube Franziska Weber Christiane G?pfert Romy Loschinski Mandy Rothe Franziska Boelke Michaela A. Diamanti Tobias L?hn Julia Ruth Dagmar Schütz Norman H?fner Florian R. Greten Ralf Stumm Karin Hartmann Oliver H. Kr?mer Anne Dudeck Thomas Kamradt 《Oncotarget》2015,6(30):28833-28850
NF-κB activation depends on the IKK complex consisting of the catalytically active IKK1 and 2 subunits and the scaffold protein NEMO. Hitherto, IKK2 activation has always been associated with IκBα degradation, NF-κB activation, and cytokine production. In contrast, we found that in SCF-stimulated primary bone marrow-derived mast cells (BMMCs), IKK2 is alternatively activated. Mechanistically, activated TAK1 mediates the association between c-Kit and IKK2 and therefore facilitates the Lyn-dependent IKK2 activation which suffices to mediate mitogenic signaling but, surprisingly, does not result in NF-κB activation. Moreover, the c-Kit-mediated and Lyn-dependent IKK2 activation is targeted by MyD88-dependent pathways leading to enhanced IKK2 activation and therefore to potentiated effector functions. In neoplastic cells, expressing constitutively active c-Kit mutants, activated TAK1 and IKKs do also not induce NF-κB activation but mediate uncontrolled proliferation, resistance to apoptosis and enables IL-33 to mediate c-Kit-dependent signaling. Together, we identified the formation of the c-Kit-Lyn-TAK1 signalosome which mediates IKK2 activation. Unexpectedly, this IKK activation is uncoupled from the NF-κB-machinery but is critical to modulate functional cell responses in primary-, and mediates uncontrolled proliferation and survival of tumor-mast cells. Therefore, targeting TAK1 and IKKs might be a novel approach to treat c-Kit-driven diseases. 相似文献
106.
107.
108.
E. Bizzi U. Massafra B. Laganà V. Bruzzese A. Picchianti Diamanti M. Cassol A. Migliore 《Clinical rheumatology》2014,33(7):877-884
Several scores are currently used to estimate the radiologic progression of patients affected by rheumatoid arthritis. Modified Sharp score, Genant-modified Sharp score and van der Heijde-modified Sharp score are actually the most commonly used scores in randomized controlled trials on biologic drugs actually available in scientific literature. An intensive literature search (EMBASE, PubMed, MEDLINE) was performed in order to identify randomized controlled studies reporting on the efficacy of biologic drugs on radiologic progression in rheumatoid arthritis by means of approved scoring methods such as Sharp score variants. All studies were evaluated for their approach to radiologic outcome, and a global evaluation of trends towards radiologic evaluation was performed. Eighteen studies were identified and analyzed, and data from such randomized controlled trials (RCTs) were reported and described regarding their approach to radiologic outcomes. The use of three different scoring methodologies generated similar but non-comparable data; although a big part of the studies reported good efficacy profiles of several biologic drugs on radiologic progression, data from such studies are not comparable as the three different scoring methods are not convertible from one to another. At present, there is no standardization for the evaluation of radiologic outcomes, thus preventing comparison of results obtained by different drugs. The use of a single, standardized and widely approved scoring method would grant the possibility of comparing such data. 相似文献
109.
Sarafidis K Tsepkentzi E Agakidou E Diamanti E Taparkou A Soubasi V Papachristou F Drossou V 《Pediatric nephrology (Berlin, Germany)》2012,27(9):1575-1582
Background
We evaluated serum (s) cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) and urine (u) CysC, NGAL and kidney injury molecule-1 (KIM-1) as markers of acute kidney injury (AKI) in asphyxiated neonates.Methods
AKI biomarkers were measured in 13 asphyxiated neonates born at ≥36?weeks gestational age (eight with AKI and five without AKI) and 22 controls. AKI was defined as serum creatinine ≥1.5?mg/dl for >24?h or rising values >0.3?mg/dl from day of life (DOL) 1. Biomarkers were measured on DOL 1, 3, and 10.Results
Asphyxiated neonates had significantly higher sCysC on DOL 1 as well as sNGAL and uCysC and uNGAL (standardized to urine creatinine and absolute values) than controls at all time points. Compared to controls, significantly higher sNGAL, uCysC, and uNGAL values were observed in the asphyxia-AKI and asphyxia–no AKI subgroups. Regarding uKIM-1, only the absolute values were significantly higher in asphyxiated neonates (DOL 10). sNGAL, uCyst, and uNGAL had a significant diagnostic performance as predictors AKI on DOL 1.Conclusions
sNGAL, uCysC, and uNGAL are sensitive, early AKI biomarkers, increasing significantly in asphyxiated neonates even in those not fulfilling AKI criteria. Their measurement on DOL 1 is predictive of post-asphyxia-AKI. 相似文献110.